Treatment interruption during radiation therapy: Experience at a single institution in the Republic of Korea.

AIM: Our study analyzed the frequency and causes of treatment interruption among patients undergoing radiation therapy (RT). METHODS: A total of 1637 RT courses in 1500 patients were reviewed from September 2009 to October 2013. A continuous break over 7 days or a discontinuous break over 14 days was regarded as a temporary break and RT under 80% of planned treatment was regarded as incomplete. RESULTS: Two-hundred and twenty courses (13.4%) with treatment interruption were identified. Half of the patients received RT with a definitive aim, and the other half for palliative care. Completion after temporary break, near completion and incompletion were noticed in 12.3%, 21.3%, and 66.4% of cases, respectively. Among patients with a definite aim, thorax (19.2%) and abdomen (16.3%) had a higher interruption rate. For brain and bone with a palliative aim, the frequency of interruption was about 16%. Old age and worse performance negatively affected interruption. The most common cause of treatment interruption was cancer progression including death (30%) and the next was treatment-related side effects (23.1%). CONCLUSION: About 13% of RT cases were interrupted. Two third of patients received less than 80% of the planned RT. To improve RT completion rate, multidirectional efforts are needed.

Bone marrow vascular endothelial growth factor level per platelet count might be a significant predictor for the treatment outcomes of patients with diffuse large B-cell lymphomas.

OBJECTIVE: Developing a parameter to predict bone marrow invasion by non-Hodgkin's lymphoma is an important unmet medical need for treatment decisions. This study aimed to confirm the validity of the hypothesis that bone marrow plasma vascular endothelial growth factor level might be correlated with the risk of bone marrow involvement and the prognosis of patients with diffuse large B-cell non-Hodgkin's lymphoma. METHODS: Forty-nine diffuse large B-cell lymphoma patients treated with rituximab, cyclophosphamide, daunorubicin, vincristine and prednisolone regimen were enrolled. Vascular endothelial growth factor level was measured with enzyme-linked immunosorbent assay. The validity of bone marrow plasma vascular endothelial growth factor level and bone marrow vascular endothelial growth factor level per platelet count for predicting treatment response and survival after initial rituximab, cyclophosphamide, daunorubicin, vincristine and prednisolone combined chemotherapy was assessed. RESULTS: Bone marrow plasma vascular endothelial growth factor level per platelet count was significantly associated with old age (≥ 65 years), poor performance score (≥ 2), high International prognosis index (≥ 3) and bone marrow invasion. The patients with high bone marrow plasma vascular endothelial growth factor level per platelet count (≥ 3.01) showed a significantly lower complete response rate than the others. On Kaplan-Meier survival curves, the patients with high bone marrow plasma vascular endothelial growth factor levels (≥ 655 pg/ml) or high bone marrow plasma vascular endothelial growth factor level per platelet count (≥ 3.01) demonstrated a significantly shorter overall survival and progression-free survival than the others. In the patients without bone marrow involvement, bone marrow plasma vascular endothelial growth factor level per platelet count had a significant relationship with overall survival and progression-free survival. Multivariate analysis revealed that the patients without BM invasion showing high level of bone marrow plasma vascular endothelial growth factor per platelet count had significantly shorter progression-free survival and overall survival. CONCLUSIONS: Bone marrow plasma vascular endothelial growth factor level per platelet count might be associated with bone marrow invasion by diffuse large B-cell lymphoma and is correlated with clinical outcomes after treatment.